Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Samvel B Gasparyan"'
Autor:
Pardeep S. Jhund, Brian L. Claggett, Atefeh Talebi, Jawad H. Butt, Samvel B. Gasparyan, Lee-Jen Wei, Zachary R. McCaw, Ulrica Wilderäng, Olof Bengtsson, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S. P. Lam, Felipe A. Martinez, Sanjiv J. Shah, Muthiah Vaduganathan, Scott D. Solomon, John J. V. McMurray
Publikováno v:
JAMA Cardiology.
ImportanceIn the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first worsening heart failure (HF) event or cardiovascular death in p
Autor:
Samvel B. Gasparyan, Joan Buenconsejo, Elaine K. Kowalewski, Jan Oscarsson, Olof F. Bengtsson, Russell Esterline, Gary G. Koch, Otavio Berwanger, Mikhail N. Kosiborod
Publikováno v:
Therapeutic Innovation & Regulatory Science. 56:785-794
DARE-19 (NCT04350593) was a randomized trial studying the effects of dapagliflozin, an SGLT2 inhibitor, in hospitalized patients with COVID-19 pneumonia and cardiometabolic risk factors. The conduct of DARE-19 offered the opportunity to define an inn
Autor:
Hiddo J.L. Heerspink, Remo H.M. Furtado, Otavio Berwanger, Gary G. Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Samvel B. Gasparyan, Fengming Tang, Sheryl L. Windsor, Vicente Cés de Souza-Dantas, Mildren del Sueldo, Robert Frankel, Ali Javaheri, Rafael A. Maldonado, Caryn Morse, Marco Mota-Gomes, Douglas Shemin, Osvaldo Lourenço Silva, Alexandre Pereira Tognon, Marcel Twahirwa, Joan Buenconsejo, Russell Esterline, Jan Oscarsson, Philip Ambery, Anna Maria Langkilde, Mikhail N. Kosiborod
Publikováno v:
Clinical Journal of the American Society of Nephrology, 17(5), 643-654. AMER SOC NEPHROLOGY
Background and objectives: Patients who were hospitalized with coronavirus disease 2019 (COVID-19) infection are at high risk of AKI and KRT, especially in the presence of CKD. The Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-
Publikováno v:
Clinical trials (London, England).
Background: Hierarchical composite endpoints are complex endpoints combining outcomes of different types and different clinical importance into an ordinal outcome that prioritizes the clinically most important (e.g. most severe) event of a patient. H
Publikováno v:
Statistics in Medicine. 41:2688-2690
Autor:
Gary G. Koch, Elaine K Kowalewski, Olof Bengtsson, John Adler, Samvel B. Gasparyan, Joan Buenconsejo, Folke Folkvaljon
Publikováno v:
Journal of Biopharmaceutical Statistics. 31:765-787
The win odds is a distribution-free method of comparing locations of distributions of two independent random variables. Introduced as a method for analyzing hierarchical composite endpoints, it is well suited to be used in the analysis of ordinal sca
Autor:
Jan Oscarsson, Emily E Akin, Ali Javaheri, Diogo D.F. Moia, Russell Esterline, Fengming Tang, Gary G. Koch, Audes D. M. Feitosa, Robert Gordon, Samvel B. Gasparyan, Joan Buenconsejo, Cristiano P Jaeger, Weimar Kunz Sebba Barroso, Philip Ambery, Omar Mukhtar, Paulo Leães, Anna Maria Langkilde, Subodh Verma, Conrado R. Hoffmann Filho, Ronaldo V P Soares, Kensey Gosch, Lilia Nigro Maia, Michael Pursley, Otavio Berwanger, Michael E. Nassif, Sheryl L. Windsor, Mikhail Kosiborod, José Roberto Lazcano Soto, Felipe Martinez, Vijay K. Chopra, Remo H.M. Furtado, Matthew Aboudara, Fabio Serra Silveira, Alberto Fonseca, Vishnu Garla
Publikováno v:
The Lancet. Diabetes & Endocrinology
Summary Background COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has significant protective benefits for the heart and kidney. We aimed to see whether this agent might provide organ protection in patients with COVID-19 by
Autor:
Otavio Berwanger, Jan Oscarsson, Samvel B. Gasparyan, Joan Buenconsejo, Anna Maria Langkilde, Russell Esterline, Gary G. Koch, Mikhail Kosiborod, Philip Ambery, C. David Sjöström, Omar Mukhtar, Subodh Verma, Ali Javaheri, Felipe Martinez, Vijay K. Chopra
Publikováno v:
Diabetes, Obesity and Metabolism. 23:886-896
AIMS: Coronavirus disease 2019 (COVID-19) is caused by a novel severe acute respiratory syndrome coronavirus 2. It can lead to multiorgan failure, including respiratory and cardiovascular decompensation, and kidney injury, with significant associated
Autor:
Pardeep S. Jhund, Toru Kondo, Jawad H. Butt, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, Muthiah Vaduganathan, Samvel B. Gasparyan, Olof Bengtsson, Daniel Lindholm, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, David DeMets, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Lars Køber, Carolyn S. P. Lam, Felipe A. Martinez, Marc S. Sabatine, Sanjiv J. Shah, Scott D. Solomon, John J. V. McMurray
Publikováno v:
Jhund, P S, Kondo, T, Butt, J H, Docherty, K F, Claggett, B L, Desai, A S, Vaduganathan, M, Gasparyan, S B, Bengtsson, O, Lindholm, D, Petersson, M, Langkilde, A M, de Boer, R A, DeMets, D, Hernandez, A F, Inzucchi, S E, Kosiborod, M N, Køber, L, Lam, C S P, Martinez, F A, Sabatine, M S, Shah, S J, Solomon, S D & McMurray, J J V 2022, ' Dapagliflozin across the range of ejection fraction in patients with heart failure : a patient-level, pooled meta-analysis of DAPA-HF and DELIVER ', Nature Medicine, vol. 28, no. 9, pp. 1956-1964 . https://doi.org/10.1038/s41591-022-01971-4
Nature Medicine. Nature Publishing Group
Nature Medicine. Nature Publishing Group
Whether the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown. A patient-level pooled meta-analysis of two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f150b3faca06f9ced0a918689e17032
https://curis.ku.dk/portal/da/publications/dapagliflozin-across-the-range-of-ejection-fraction-in-patients-with-heart-failure(3cc6c566-095e-4744-a012-b803736826da).html
https://curis.ku.dk/portal/da/publications/dapagliflozin-across-the-range-of-ejection-fraction-in-patients-with-heart-failure(3cc6c566-095e-4744-a012-b803736826da).html
Autor:
Mikhail N Kosiborod, Russell Esterline, Jan Oscarsson, Samvel B Gasparyan, Remo H M Furtado, Subodh Verma, Otavio Berwanger
Publikováno v:
The Lancet. Diabetes & Endocrinology